Periorbital edema associated with alpelisib

Elizabeth A. Dao, Saira J. George, Meghan M. Heberton, Omar Pacha, Craig A. Kovitz, Anisha B. Patel, Rhea M. Phillips

Research output: Contribution to journalArticlepeer-review


Alpelisib is an alpha isoform-specific phosphatidylinositol 3-kinase (PI3K) inhibitor approved for use in the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative metastatic breast cancer in combination with fulvestrant. Hyperglycemia, rash, and gastrointestinal upset are the most commonly reported adverse events associated with alpelisib. Although rash is a known on-target effect of alpelisib, patients typically present with a morbilliform rash. We describe two cases of periorbital edema associated with alpelisib. We discuss the clinical findings, management, and prognosis of this unique reaction. These cases highlight the importance of early involvement of dermatology to manage adverse cutaneous events associated with alpelisib.

Original languageEnglish (US)
Article number100596
JournalCancer Treatment and Research Communications
StatePublished - Jan 2022
Externally publishedYes


  • Alpelisib
  • Breast cancer
  • Cutaneous adverse events
  • Dermatology
  • Phosphatidylinositol 3-kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Periorbital edema associated with alpelisib'. Together they form a unique fingerprint.

Cite this